Top Albumin Companies

Albumin Market size was valued at USD 7.08 Billion in 2024 and is poised to grow from USD 7.5 Billion in 2025 to USD 11.87 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026–2033).

The global albumin market is competitive. With regulatory approvals and strategic partnerships dominating the market, the focus here is on new product innovation, which is necessary to enhance a company's strength in the industry. Companies with plasma-derived production of albumin include Grifols SA, CSL Behring, Takeda Pharmaceutical, Octapharma, and Baxter International. But Shilpa Biologicals, Albumedix, and Merck KGaA are slowly emerging as newcomers in recombinant albumin technologies. The investments in biopharmaceuticals, research and development along with regional expansions exacerbate the competition in the market. 'Merck KGaA (Germany)', 'CSL Limited (Australia) ', 'Grifols S.A. (Spain) ', 'Baxter International Inc. (USA) ', 'China Biologic Products Holdings, Inc. (China) ', 'Takeda Pharmaceuticals (Japan) ', 'Octapharma AG (Switzerland) ', 'Novozymes A/S (Denmark) ', 'Thermo Fisher Scientific Inc. (USA) ', 'Ventria Bioscience (USA) ', 'Albumedix Ltd. (UK) ', 'Biotest AG (Germany) ', 'HiMedia Laboratories (India) ', 'Invitria (USA) ', 'Medxbio Pte Ltd. (Singapore) ', 'RayBiotech, Inc. (USA) ', 'SeraCare (USA) ', 'Kedrion S.p.A. (Italy) ', 'Albumin Therapeutics, LLC (USA)'

A growth driver in high volume is the increased usage of albumin in regenerative medicine, vaccine stabilization, and drug formulations. The importance in modern biopharmaceuticals stems from its use in plasma expansion, drug delivery, and applications in nanomedicine. Another driver is the growing number of patients with chronic diseases, such as hypovolemia and liver disorders, and this compels pharmaceutical companies to produce new drugs.

Transition to Sustainable Production and Recombinant Albumin: T Due to concerns over the acquisition of plasma and the risk of pathogen transfer, along with supply constraints, the market is slowly shifting its preference from using plasma-derived albumin to using recombinant albumin. Companies are therefore investing in genetic engineering to scale up the manufacture of albumin for improved safety and environmental sustainability. Innovations such as plant-based and yeast-expressed recombinant albumin are gaining pace and offering affordable and contamination-free alternatives.

North America currently leads the markets globally, where the biopharmaceutical industries are strong in terms of capital investment and with significant research investments. Advanced medical infrastructure in that region also attracts a high quantity of demand from the albumin market. Moreover, the diseases that are prevailing in this particular region, that is, more chronic diseases among the population with liver disorders and cancer, raise the demand to a greater level. Albumin is a drug carrier that is often used in the field of nanomedicine owing to its characteristic properties such as being non-toxic, biodegradable, non-immunogenic, and highly abundant in plasma. In addition, North America remains ahead in the race primarily due to the infinite developments in biotechnology. Furthermore, favorable reimbursement policies and strong governmental support also boost the growth in the market.